Similar articles for PMID: 20688946

Year	Number of Results
2000	1
2002	2
2004	1
2005	7
2006	5
2007	7
2008	6
2009	10
2010	14
2011	16
2012	1
2013	5
2014	4
2015	9
2016	4
2017	2
2018	4
2019	2
2024	0

1

Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors.

Okamoto I, Kaneda H, Satoh T, Okamoto W, Miyazaki M, Morinaga R, Ueda S, Terashima M, Tsuya A, Sarashina A, Konishi K, Arao T, Nishio K, Kaiser R, Nakagawa K. Okamoto I, et al. Mol Cancer Ther. 2010 Oct;9(10):2825-33. doi: 10.1158/1535-7163.MCT-10-0379. Epub 2010 Aug 5. Mol Cancer Ther. 2010. PMID: 20688946 Clinical Trial.

2

Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors.

Mross K, Stefanic M, Gmehling D, Frost A, Baas F, Unger C, Strecker R, Henning J, Gaschler-Markefski B, Stopfer P, de Rossi L, Kaiser R. Mross K, et al. Clin Cancer Res. 2010 Jan 1;16(1):311-9. doi: 10.1158/1078-0432.CCR-09-0694. Epub 2009 Dec 22. Clin Cancer Res. 2010. PMID: 20028771 Clinical Trial.

3

A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer.

Reck M, Kaiser R, Eschbach C, Stefanic M, Love J, Gatzemeier U, Stopfer P, von Pawel J. Reck M, et al. Ann Oncol. 2011 Jun;22(6):1374-1381. doi: 10.1093/annonc/mdq618. Epub 2011 Jan 6. Ann Oncol. 2011. PMID: 21212157 Free article. Clinical Trial.

4

A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies.

du Bois A, Huober J, Stopfer P, Pfisterer J, Wimberger P, Loibl S, Reichardt VL, Harter P. du Bois A, et al. Ann Oncol. 2010 Feb;21(2):370-375. doi: 10.1093/annonc/mdp506. Epub 2009 Nov 4. Ann Oncol. 2010. PMID: 19889612 Free article. Clinical Trial.

5

Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.

Eskens FA, Steeghs N, Verweij J, Bloem JL, Christensen O, van Doorn L, Ouwerkerk J, de Jonge MJ, Nortier JW, Kraetzschmar J, Rajagopalan P, Gelderblom H. Eskens FA, et al. J Clin Oncol. 2009 Sep 1;27(25):4169-76. doi: 10.1200/JCO.2008.18.8193. Epub 2009 Jul 27. J Clin Oncol. 2009. PMID: 19636022 Clinical Trial.

6

Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients.

Bousquet G, Alexandre J, Le Tourneau C, Goldwasser F, Faivre S, de Mont-Serrat H, Kaiser R, Misset JL, Raymond E. Bousquet G, et al. Br J Cancer. 2011 Nov 22;105(11):1640-5. doi: 10.1038/bjc.2011.440. Epub 2011 Oct 25. Br J Cancer. 2011. PMID: 22027711 Free PMC article. Clinical Trial.

7

Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer.

Ledermann JA, Hackshaw A, Kaye S, Jayson G, Gabra H, McNeish I, Earl H, Perren T, Gore M, Persic M, Adams M, James L, Temple G, Merger M, Rustin G. Ledermann JA, et al. J Clin Oncol. 2011 Oct 1;29(28):3798-804. doi: 10.1200/JCO.2010.33.5208. Epub 2011 Aug 22. J Clin Oncol. 2011. PMID: 21859991 Clinical Trial.

8

An open-label dose-escalation study of BIBF 1120 in patients with relapsed or refractory multiple myeloma.

Kropff M, Kienast J, Bisping G, Berdel WE, Gaschler-Markefski B, Stopfer P, Stefanic M, Munzert G. Kropff M, et al. Anticancer Res. 2009 Oct;29(10):4233-8. Anticancer Res. 2009. PMID: 19846979 Free article. Clinical Trial.

9

Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib.

Zhou A, Zhang W, Chang C, Chen X, Zhong D, Qin Q, Lou D, Jiang H, Wang J. Zhou A, et al. Cancer Chemother Pharmacol. 2013 Nov;72(5):1043-53. doi: 10.1007/s00280-013-2282-y. Epub 2013 Sep 17. Cancer Chemother Pharmacol. 2013. PMID: 24043137 Clinical Trial.

10

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.

Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, Garin-Chesa P, Bader G, Zoephel A, Quant J, Heckel A, Rettig WJ. Hilberg F, et al. Cancer Res. 2008 Jun 15;68(12):4774-82. doi: 10.1158/0008-5472.CAN-07-6307. Cancer Res. 2008. PMID: 18559524

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

80 results

Results by year